Eribulin Mesylate

FDA granted approval for eribulin mesylate (Halaven Injection, Eisai Inc.) for the treatment of patients with metastatic breast cancer who have previously received an anthracycline and a taxane in either the adjuvant or metastatic setting, and at least two chemotherapeutic regimens for the treatment of metastatic disease. (November 15, 2010) More Information: http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm234527.htm

About the Center for Drug Evaluation and Research > Eribulin Mesylate